Height Loss and Stooped Posture After Menopause, What the Bone Density Research Shows

In this article
- Why do women get shorter after menopause?
- What actually happens inside a compressing vertebra?
- What did the human shilajit bone trial find?
- What does the mechanism look like at the cellular level?
- How does this compare with calcium and vitamin D alone?
- What can you do about posture and height loss today?
- Common questions about height loss and bone density after menopause
Why do women get shorter after menopause?

A little height loss is normal with age, as spinal discs lose fluid and flatten over decades. But a noticeable drop, especially a stoop that develops over a year or two rather than a lifetime, points to something more specific. The vertebrae themselves are losing density and beginning to compress under ordinary body weight.
This is not the same thing as slouching. A forward curve at the upper back, sometimes called a dowager's hump, forms when one or more vertebrae in the spine lose enough density that their front edge collapses slightly while the back edge holds. Stack a few of those small compressions on top of each other and the spine shortens and curves forward, visibly.
Why the spine loses density first
The spine is built mostly from trabecular bone, the lighter, more porous bone tissue found inside the ends of long bones and throughout the vertebrae. Trabecular bone has a much higher surface area than the dense outer shell of bone found in the arms and legs, which means it responds faster, in both directions, to shifts in the hormones and signaling molecules that control bone remodeling. That is part of why the spine and hip are typically the first places a DEXA scan shows meaningful loss after menopause.
What actually happens inside a compressing vertebra?
Bone is not a fixed structure. It is constantly being broken down by cells called osteoclasts and rebuilt by cells called osteoblasts, a cycle called remodeling that replaces the entire skeleton roughly every 10 years in a healthy adult. Estrogen is one of the main signals that keeps that cycle balanced, restraining the breakdown side so rebuilding can keep pace.
When estrogen falls at menopause, several things shift at once.
- Osteoclast activity increases, so bone breakdown accelerates
- Osteoblast-driven rebuilding does not keep pace with the faster breakdown
- Trabecular bone in the spine, being more porous, loses structural integrity faster than dense bone elsewhere
- The vertebral body becomes less able to bear ordinary compressive load from standing and walking
- Small, often painless compressions accumulate, each one shaving a small amount off total height
None of this requires a fall or an accident. A vertebra can compress simply from the weight of daily movement once its internal structure has thinned enough, which is why height loss can arrive gradually and go unnoticed until pants are suddenly too long.
What did the human shilajit bone trial find?

The strongest human evidence on shilajit and bone comes from a 48-week double-blind randomized controlled trial in 60 postmenopausal women, published in 2022. At baseline, the women had osteopenia at the lumbar spine and osteoporosis at the hip, the exact trabecular-bone pattern described above.
The results were dose-dependent and consistent across both sites.
- Bone mineral density rose at both the spine and the hip in the shilajit groups, while the placebo group continued losing density
- Every single woman in the treatment group reversed her hip osteoporosis within 6 months
- Bone resorption markers fell 17 to 22 percent from baseline at the higher dose by week 48
- Bone formation markers also fell, which the trial authors identified as an antiresorptive signature, the same pattern behind how bone-preserving therapies are expected to work
- Inflammation and oxidative stress markers dropped alongside the density gains, and nitric oxide rose 50 to 60 percent as a secondary finding
The trial reported zero adverse events across both dose groups.
Where this research is honest about its limits
This trial measured bone mineral density and bone turnover markers, not height or vertebral compression directly. Density and turnover markers are the standard, clinically accepted way to measure whether bone is being rebuilt or lost, and they are the mechanism height loss depends on, but no trial has measured height change itself as an outcome. We say that plainly rather than imply a result the research has not shown.
What does the mechanism look like at the cellular level?
Two smaller studies help explain what is happening at the cell level behind the density numbers. An in vitro study found shilajit accelerated osteogenic differentiation of human stem cells, raising both alkaline phosphatase activity and calcium deposition, the two standard lab markers of active bone-building cells. A separate in vitro study found low-dose mumie, a form of shilajit, raised osteoblast proliferation directly. Higher concentrations became toxic to the cells instead. More is not automatically better with any mineral compound.
Shilajit is not a hormone, and it does not add estrogen to the body. What the mechanism research points to is fulvic acid supporting the body's own estrogen signaling and mineral transport, working with the remodeling cycle that is already running rather than replacing it.
How does this compare with calcium and vitamin D alone?
Calcium and vitamin D are foundational and neither trial nor common sense argues otherwise. But calcium alone is a raw material, not a signal, and most women who increase calcium intake after a bone scan see their loss slow rather than reverse. The shilajit trial measured something different, a shift in the balance between breakdown and rebuilding itself.
| Calcium and vitamin D alone | Shilajit research | |
|---|---|---|
| What it provides | Raw mineral supply | Signaling and mineral transport support |
| Typical effect on BMD | Slows further loss | Increased BMD at spine and hip, dose-dependent |
| Evidence type | Widely recommended, mixed trial results on density change | 48-week randomized controlled trial, postmenopausal women |
| Bone turnover markers | Not typically shifted meaningfully | Resorption markers fell 17 to 22 percent |
Neither column is a substitute for a DEXA scan or a conversation grounded in your own numbers. This is about what the mechanism research shows, not a personal treatment plan.
What can you do about posture and height loss today?

A handful of ordinary habits support the same remodeling cycle the research measures, whether or not a supplement is part of the routine.
- Track your height once a year at the doctor's office, since a drop of an inch or more is worth noting on paper, not just noticing in the mirror
- Add weight-bearing movement several times a week, since bone responds to mechanical load by staying denser
- Get adequate protein and calcium through food first, since both are raw materials the remodeling cycle depends on
- Work on upper-back extension exercises, which strengthen the muscles that resist the forward-curving pull of a compressing spine
- Ask for a DEXA scan if you have not had one, since a T-score is the only way to know whether density loss is already underway
Shilajit's fulvic acid and mineral content support the same bone-signaling mechanism measured in the 48-week trial above, and it is the core ingredient in Optimum Shilajit, sourced from the Altai mountains and third-party tested for purity on every batch. No trial has measured height change directly, and we say that honestly rather than stretch a bone density result into a claim it was not designed to make.
Common questions about height loss and bone density after menopause
How much height loss is normal after menopause?
Some gradual height loss is common with age as spinal discs lose fluid, but a loss of an inch or more, especially if it happens over a short window, is a recognized signal of vertebral bone loss rather than ordinary aging. It is worth tracking rather than dismissing.
Can lost height come back?
Once a vertebra has compressed, the change in shape is largely permanent. The research focus is on preventing further compression by supporting bone density and turnover, not reversing height already lost.
Has shilajit actually been tested on bone density in postmenopausal women?
Yes. A 48-week randomized controlled trial in 60 postmenopausal women found shilajit increased bone mineral density at both the spine and the hip in a dose-dependent way, while the placebo group kept losing density. Every woman in the treatment group reversed her hip osteoporosis within 6 months.
Is shilajit a replacement for calcium and vitamin D?
No, and we do not claim that. Calcium and vitamin D remain foundational nutrients for bone. The research on shilajit shows a different mechanism, shifting the balance between bone breakdown and bone formation, measured through bone turnover markers alongside the density increase.
What is the difference between osteopenia and osteoporosis on a bone scan?
Both are measured with a T-score from a DEXA scan. Osteopenia is a T-score between -1.0 and -2.5, a mild loss of density. Osteoporosis is a T-score of -2.5 or lower, a more advanced loss with higher fracture risk. The spine and hip can carry different T-scores in the same person.
Sources
- Pingali U, et al. Effect of Purified Shilajit on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women. 2022. https://pubmed.ncbi.nlm.nih.gov/35933897/
- Kangari P, et al. Shilajit accelerates osteogenic differentiation of human adipose-derived stem cells. 2022. https://pubmed.ncbi.nlm.nih.gov/36153551/
- Abbasi B, et al. Effect of mumie on MG-63 osteoblast-like cell proliferation. 2019. https://pubmed.ncbi.nlm.nih.gov/31983854/
- Sadeghi H, et al. Effect of oral momiai on tibial fracture healing time, double-blind randomized controlled trial. 2020. https://pubmed.ncbi.nlm.nih.gov/32310691/